


Thalidomide-O-amido-C6-NH₂ hydrochloride

| | |
|--------------------|---|
| Cat. No.: | HY-112618B |
| CAS No.: | 2376990-31-5 |
| Molecular Formula: | C ₂₁ H ₂₇ ClN ₄ O ₆ |
| Molecular Weight: | 466.92 |
| Target: | E3 Ligase Ligand-Linker Conjugates |
| Pathway: | PROTAC |
| Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. |



BIOLOGICAL ACTIVITY

| | |
|---------------------------|--|
| Description | Thalidomide-O-amido-C6-NH ₂ hydrochloride, a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker, can be used in the synthesis of PROTACs ^[1] . |
| IC ₅₀ & Target | Cereblon |
| In Vitro | PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

REFERENCES

[1]. Bradner J, et al. Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses. WO 2017024318 A1

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA